Company Profile

Volition is a multi-national epigenetics company that applies its Nucleosomics™ platform through its subsidiaries to develop simple, easy to use, cost effective blood tests to help diagnose and monitor a range of life-altering diseases including some cancers and diseases associated with NETosis such as sepsis and COVID-19. Early diagnosis and monitoring have the potential to not only prolong the life of patients, but also to improve their quality of life. The tests are based on the science of Nucleosomics™, which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluid - an indication that disease is present. Volition is primarily focused on human diagnostics and monitoring but also has a subsidiary focused on animal diagnostics and monitoring.

Volition's research and development activities are centered in Belgium, with an innovation hub in California and additional offices in Texas, London and Singapore, as the company focuses on bringing its diagnostic and disease monitoring products to market.

Latest Presentation

Industry Classifications

Sector:
Healthcare

Industry:
Diagnostics

Contact Information

Investor Relations
VolitionRx
Scott Powell
T: +1-646-650-1351
investorrelations@volition.com

Edison Advisors
Joseph Green
T: +1-646-653-7030
jgreen@edisongroup.com

Edison Advisors
Rachel Carroll
T: +44 (0) 20 3077 5711
rcarroll@edisongroup.com

Company Contact
VolitionRx Ltd
13215 Bee Cave Parkway
Galleria Oaks B Suite 125
Austin, TX 78738
US
T: +1-646-650-1351
info@volition.com